Innate Pharma - ADR Stock News

Innate Pharma S.A. (NASDAQ:IPHA ) Q4 2024 Earnings Conference Call March 27, 2025 9:00 AM ET Company Participants Henry Wheeler - VP, IR and Communications Jonathan Dickinson - CEO Yannis Morel - COO Sonia Quaratino - CMO Frederic Lombard - CFO Conference Call Participants Daina Graybosch - Leerink Partners Swayampakula Ramakanth - H.C.

MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the year ending December 31, 2024. The consolidated financial statements are attached to this press release. “Our strategy is clear: drive innovation through our ANKET® NK-cell engager platform and acce...

MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding IPH4502, its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4, has been selected for the American Association for Cancer Research (AACR) Annual Meeting 2025, taki...

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference.

Innate Pharma's diverse pipeline, including lacutamab, IPH6501, and IPH4502, shows promising clinical activity and potential for significant milestones in 2025. Lacutamab, a key asset, received US FDA Breakthrough Therapy designation, enhancing its development prospects and partnership potential. Financially, IPHA has a cash runway until the end of 2025, but may face a cash crunch, likely requi...

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast for full year 2024 financial results.

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to participate in The 2025 Leerink Partners Global Healthcare Conference.

Positive results achieved in the open-label phase 2 TELLOMAK study, using lacutamab for the treatment of patients with relapsed/refractory Sezary Syndrome; Patients achieved a confirmed Objective Response Rate of 37.5%. Release of data from phase 2 study, using lacutamab for the treatment of patients with Peripheral T-cell Lymphoma, expected in 2025. Company actively seeking to establish a coll...